Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc. (SMTI) is a leading medical technology company that aims to revolutionize the wound care and skincare markets through innovative solutions. Founded in 1982 and headquartered in Fort Worth, Texas, Sanara MedTech focuses on developing and commercializing technologies that improve clinical outcomes for patients while simultaneously reducing healthcare costs.
The company operates through its subsidiary, Wound Care Innovations, LLC, and offers a range of collagen-based wound care products under the brand name CellerateRX. These products are marketed for treating various types of wounds, including pressure ulcers, diabetic ulcers, surgical wounds, and burns. Available in both gel and powder forms, CellerateRX is designed to serve healthcare providers such as physicians, clinics, and hospitals.
Sanara MedTech's portfolio extends beyond surgical wound care, encompassing a comprehensive suite of chronic wound care products. The company's notable offerings include HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel. These products enable Sanara MedTech to deliver extensive wound and skincare solutions across all care settings, from acute to post-acute environments.
With a strategic focus on transformative technologies, Sanara MedTech holds worldwide licenses for certain proprietary technologies and processes. This positions the company at the forefront of advancing wound care treatment protocols. Recent achievements highlight the company's commitment to innovation and quality, making it a key player in the medical technology landscape.
Sanara MedTech also prioritizes transparent communication with its investors and stakeholders. For the latest updates and developments, the company's investor relations team is readily accessible, ensuring stakeholders are well-informed about performance metrics, ongoing projects, and future prospects.
Overall, Sanara MedTech Inc. continues to set the standard in wound care and skincare solutions, contributing significantly to the healthcare sector by enhancing patient care and operational efficacy.
Sanara MedTech Inc. (NASDAQ: SMTI), based in Fort Worth, Texas, has announced the commercial launch of two innovative products in collaboration with Cook Biotech Inc. These products, FORTIFY TRG™ Tissue Repair Graft and FORTIFY FLOWABLE™ Extracellular Matrix, are designed to enhance surgical and chronic wound care. Both products are FDA 510(k) cleared, with FORTIFY TRG aimed at reinforcing soft tissue and FORTIFY FLOWABLE designed for various wound management applications. The partnership aims to improve patient outcomes while reducing costs.
Sanara MedTech Inc. (NASDAQ: SMTI) announced its third quarter earnings release will occur on November 12, 2021, after market close. A conference call is scheduled for November 15, 2021, at 9:00 a.m. ET. Investors can access the call by dialing 888-506-0062 or via the company's website for a live webcast. The company focuses on advanced wound care solutions and aims to improve patient outcomes through innovative products and telemedicine services. Key areas of focus include biofilm removal and advanced biologics.
Sanara MedTech Inc. (NASDAQ:SMTI), a Fort Worth-based provider of surgical and chronic wound care products, announced its virtual presentation at the 2021 Cantor Virtual Global Healthcare Conference. The presentation is scheduled for September 29, 2021, at 9:20 a.m. ET. Prior to the event, presentation materials will be available on the company's Investor Relations website. Sanara focuses on evidence-based healing solutions, offering products like CellerateRX® and BIAKŌS™ for wound care, while also expanding into telemedicine for consultations.
Sanara MedTech Inc. (NASDAQ: SMTI) has been selected to present at the virtual MicroCap Leadership Summit on September 24, 2021. Executive Chairman Ron Nixon will represent the company among ten selected firms, connecting with over 100 retail and institutional investors globally. Sanara specializes in surgical and chronic wound care products, aiming to improve patient outcomes. The presentation materials will be accessible on the company's website before the event. For further details, visit MicroCapClub.
Sanara MedTech Inc. (NASDAQ:SMTI) reported significant growth in its second quarter results for 2021. Revenues reached $6.28 million, up 112% from the previous year, driven by increased sales of surgical products across more facilities. The company expanded its sales team and formed a strategic partnership with Pixalere Healthcare. Despite a net loss of $1.21 million for the quarter, improvements were noted compared to the prior year. Sanara also acquired assets from Rochal Industries, enhancing its R&D capabilities.
Sanara MedTech Inc. (NASDAQ:SMTI) has announced the release of its second-quarter financial results for 2021, scheduled for August 16, 2021. The findings will be disclosed post-market close, followed by a conference call on August 17, 2021, at 9:00 a.m. ET. The company's focus remains on developing wound and skincare products to enhance patient outcomes. Sanara continues to pursue innovations in telehealth and seeks strategic partnerships to improve healthcare cost-effectiveness.
Sanara MedTech Inc. (NASDAQ: SMTI) announced the acquisition of certain assets from Rochal Industries for approximately $1.0 million, consisting of $0.5 million in stock and $0.5 million in cash. This acquisition will enhance Sanara's wound and skin care technology and includes hiring Rochal's R&D team, intellectual property, and FDA clearances. The company anticipates additional operating expenses of $1.2 to $1.5 million in the first year, potentially offset by future grants and contract revenues. This move is aligned with Sanara's strategy to improve patient outcomes.
Sanara MedTech Inc. (NASDAQ: SMTI) has announced a strategic partnership with Pixalere Healthcare Inc., aimed at enhancing wound and skin care solutions. As part of the deal, Sanara acquired a 27.3% equity stake in Pixalere and has established a subsidiary, Pixalere USA, with exclusive rights to utilize Pixalere's software in the U.S. market. The integration of Pixalere's technology and Sanara's WounDerm platform is expected to improve patient care by providing advanced decision support and analytics to healthcare providers.
Sanara MedTech Inc. (NASDAQ: SMTI) reported a 42% revenue increase in Q1 2021, generating $5,009,436 compared to $3,524,331 in Q1 2020. Despite a January sales slowdown due to COVID-19, the company rebounded with record sales in March, exceeding $2 million for the first time. Notable highlights include the successful closing of a $29 million public offering, expansion of surgical product approvals to over 850 facilities, and a 23% growth in chronic wound care product sales. The net loss improved to $1,183,376 from $1,841,012 a year prior.
Sanara MedTech Inc. (NASDAQ:SMTI) announced strong financial results for the fourth quarter and full year ended December 31, 2020. The company reported a 32% increase in annual revenues to $15.6 million, with a record Q4 sales of $4.79 million, up 43% year-over-year. Despite challenges from COVID-19, Sanara expanded its product distribution and launched new products like the BIAKŌS™ Antimicrobial Wound Gel. The company also completed a public offering raising $31.6 million to fund further growth, although it reported a net loss of $4.45 million for the year.
FAQ
What is the current stock price of Sanara Medtech (SMTI)?
What is the market cap of Sanara Medtech (SMTI)?
What is Sanara MedTech Inc. known for?
What products does Sanara MedTech offer?
Who are the primary customers for Sanara MedTech's products?
Where is Sanara MedTech Inc. headquartered?
When was Sanara MedTech Inc. founded?
How does Sanara MedTech contribute to healthcare cost reduction?
What forms does CellerateRX come in?
What conditions can CellerateRX treat?
How does Sanara MedTech ensure transparent communication with investors?
Who is the current Director of Investor Relations at Sanara MedTech?
